Nikhil C. Munshi, MD
Adjunct Associate Professor
Boston University School of Medicine
Dept of Hematology & Oncology

MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University




Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.





Yr Title Project-Sub Proj Pubs
2019 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-06 26
2018 Molecular Manipulation to Enhance Anti-Myeloma Response 2I01BX001584-05A2 26
2018 Integrative Oncogenomics of Multiple Myeloma 5P01CA155258-07 218
2018 Integrative Oncogenomics of Multiple Myeloma (2 of 2) 3P01CA155258-07S2 218
2018 Integrative Oncogenomics of Multiple Myeloma (1 of 2) 3P01CA155258-07S1 218
2018 Core 1: Administrative and Communication Core 5P01CA155258-07-5939 218
2018 Project 4. Targeting genomic instability and evolution in myeloma 5P01CA155258-07-5947 218
2018 Core 1: Administrative and Communication Core 3P01CA155258-07S2-5939 218
2018 Core 1: Administrative and Communication Core 3P01CA155258-07S1-5939 218
2018 Project 4. Targeting genomic instability and evolution in myeloma 3P01CA155258-07S2-5947 218
Showing 10 of 64 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L, Royo R, Ziccheddu B, Puente XS, Avet-Loiseau H, Cambell PJ, Nik-Zainal S, Campo E, Munshi N, Bolli N. A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019 Jul 05; 10(1):2969. PMID: 31278357.
     
  2. Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC, Anderson KC. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2019 Jun 10. PMID: 31182781.
     
  3. Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. 2019 May 15. PMID: 31090915.
     
  4. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 05 02; 380(18):1726-1737. PMID: 31042825.
     
  5. Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Slabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 Jul 11; 134(2):160-170. PMID: 31043423.
     
  6. Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019 Jun 13; 133(24):2615-2618.View Related Profiles. PMID: 31003998.
     
  7. Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 Mar 26; 9(4):39. PMID: 30914633.
     
  8. Bae J, Samur M, Richardson P, Munshi NC, Anderson KC. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 Mar 12. PMID: 30872779.
     
  9. Jagannath S, Heffner LT, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jun; 19(6):372-380. PMID: 30930134.
     
  10. Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019 Jun; 19(6):332-344. PMID: 31023594.
     
Showing 10 of 449 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 449 publications over 24 distinct years, with a maximum of 29 publications in 2015

YearPublications
19961
19975
19987
199913
20006
200114
200226
200325
200416
200516
200619
200720
200820
200926
201021
201125
201222
201328
201425
201529
201623
201725
201826
201911
Contact for Mentoring:


Munshi's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department